BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

RSF Bio enters worldwide license agreement with Sanofi for cardiovascular drug

June 18, 2021 | News

This agreement provides RSF Bio with Sanofi's rights to develop Ataciguat and potentially in select international countries



Rancho Santa Fe Bio, Inc. (RSF Bio), a San Diego, California-based clinical-stage cardiovascular platform company, announced that it has entered into an exclusive worldwide license agreement with Sanofi, a global biopharmaceutical company. This agreement provides RSF Bio with Sanofi's rights to Ataciguat. With this license, RSF Bio will have the rights it needs to continue the development of Ataciguat through clinical trials in the United States and potentially in select international countries.

Before signing this license agreement, RSF Bio entered into a worldwide exclusive license agreement in December 2019 with Mayo Clinic for the use of Ataciguat in the treatment of patients with calcific aortic valve stenosis ("CAVS"). Under that license, Mayo Clinic assigned to RSF Bio its US IND No. 119,829 along with additional patents, patent applications and know-how.

RSF Bio is currently in an advanced stage of development of a novel pharmaceutical treatment with the drug Ataciguat, building upon a Phase IIb clinical trial. RSF Bio is also in the early planning stages of studying application for Ataciguat in certain other uses and indications.

"The NCATS New Therapeutic Uses program developed and disseminated innovative approaches to three-way collaborations between government, pharmaceutical companies and academic medical centers to accelerate treatment development," said Christine Colvis, Ph.D., Director of Drug Development Partnership Programs at NCATS.